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Background/aim: To determine risk factors associated with the development of insulin resistance, type 2 diabetes mellitus (T2DM), and
metabolic syndrome (MetS) in gestational diabetes mellitus (GDM) patients 10 years after giving birth.
Materials and methods: Medical records of patients with former GDM were screened. Eligible patients were invited to the hospital to
obtain information about their present health status. Patients with pregestational diabetes and patients with multiple pregnancies were
excluded. A total of 67 women formed the study group. American Diabetes Association (ADA) and International Diabetes Federation
(IDF) criteria were used to define T2DM and MetS, respectively.
Results: A total of 27 patients developed diabetes (40.3%) and 35 patients (52%) developed MetS. T2DM developed, on average, 4.8 years
after delivery. There was a significant difference between diabetic and nondiabetic patients in terms of insulin use during pregnancy (P
< 0.001). Women who developed diabetes within 10 years after giving birth were observed to have significantly higher fasting plasma
glucose on oral glucose tolerance test during their pregnancy (P = 0.007). Current and pregestational body mass indices had a significant
effect on the development of MetS (P = 0.003 and P = 0.027, respectively).
Conclusion: In this long-term study, we found that patients with high fasting plasma glucose (FPG) and insulin requirement during
pregnancy are at an increased risk of developing T2DM, while pregestational obesity is predictive of progression to MetS. Identifying
and targeting high-risk individuals may delay and possibly prevent T2DM and MetS.
Key words: Diabetes, metabolic syndrome, gestational diabetes, insulin resistance

1. Introduction
Gestational diabetes mellitus (GDM) is characterized by
glucose intolerance with first recognition during pregnancy.
The global prevalence of GDM ranges from 5% to 20%
depending on the study population [1]. Women with GDM
may develop type 2 diabetes mellitus (T2DM), prediabetes,
metabolic syndrome (MetS), and cardiovascular disease in
the years following their pregnancy [2–4].
Pregnancy is associated with a physiological insulin
resistance, particulary in the second trimester, due to
placental hormones such as human placental lactogen,
progesterone, cortisol, growth hormone, and prolactin.
GDM patients are shown to have insulin resistance
combined with impaired secretion of insulin due to a
defect in pancreatic β-cell function. Thus, the stress of
pregnancy may trigger clinical diabetes in a predisposed
individual [5].

In addition to being a major cause of kidney failure,
coronary artery disease, and stroke, T2DM is among the first
seven causes of disease-related deaths worldwide [6]. As well
as being a constellation of cardiovascular risk factors, MetS is
also associated with increased morbidity and mortality [7].
Thus, prevention of both conditions is of utmost importance
worldwide. Early recognition of high-risk patients in the
preclinical period, and appropriate preventive strategies
may reduce the risk of progression to T2DM and MetS.
Therefore, the purpose of this study was to determine risk
factors associated with the development of insulin resistance,
T2DM, and MetS in GDM patients 10 years after giving birth.
2. Subjects and methods
2.1. Study population and design
The study was undertaken in Istanbul Faculty of Medicine,
department of Endocrinology and Metabolism. The
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inclusion criteria were as follows: 1) women who were
diagnosed with GDM 10 ± 2 years previously and 2) women
who were at least 18 years old at the time of pregnancy.
Medical records of eligible patients were screened
retrospectively. A total of 260 patients were screened.
Patients with pregestational diabetes and patients with
multiple pregnancies were excluded. Patients who met the
eligibility criteria were called and invited to the hospital. A
total of 67 women, who fulfilled the eligibility criteria and
gave written informed consent, formed the study group. A
flowchart of participation is shown in Figure.
The institutional review board approved the study
protocol (protocol no: 12-510). The study was conducted
in compliance with the Declaration of Helsinki.
All patients underwent physical examination including
systolic and diastolic blood pressure. The weight, height,
body mass index (BMI), waist circumference, and hip
circumference of all patients were recorded. Blood
pressures were measured twice in a sitting position after at
least 10 min of rest with a mercury sphygmomanometer.
BMI was calculated as weight (kg) divided by height in
meters squared (m²). Waist circumference was measured
at the midpoint between the top of the iliac crest and
the lower margin of the least palpable rib, and hip
circumference was measured around the widest portion of
the buttocks using a flexible tape [8].
GDM was defined as glucose intolerance with first
recognition during pregnancy. Impaired fasting glucose
(IFG) was defined as fasting plasma glucose (FPG) between
100 and 125 mg/dL (5.6 and 6.9 mmol/L), and impaired

Total number of patients
evaluated
n=260

The number of patients not included in the study due to
missing or incorrect address and phone number records
n=116
The number of patients who refused to participate in the
study (n=58) / patients with pregestational diabetes (n=16)
and patients with multiple pregnancies (n=3)

19

The final number of patients enrolled
in the study
n=67
Figure. Flowchart of participation.
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glucose tolerance (IGT) was defined as 2 h glucose between
140 and 199 mg/dL (7.8 and 11.0 mmol/L) during 75 g oral
glucose tolerance test (OGTT). Patients were diagnosed
with T2DM if they had one of the following: FPG ≥126
mg/dL (7.0 mmol/L) or 2 h glucose ≥200 mg/dL (11.1
mmol/L) during OGTT, or HbA1c ≥6.5% (48 mmol/mol)
or a random plasma glucose ≥200 mg/dL (11.1 mmol/L) in
a patient with symptoms of hyperglycemia [9].
MetS was defined as ethnicity-specific waist
circumference plus any two of the following: High
triglycerides >150 mg/dL (1.7 mmol/L), low HDLcholesterol <50 mg/dL (1.29 mmol/L), receiving treatment
for a lipid abnormality, systolic blood pressure ≥130
mmHg, diastolic blood pressure ≥85 mmHg, receiving
treatment for hypertension, FPG ≥100 mg/dL (5.6
mmol/L), or previously diagnosed T2DM [10]. Insulin
resistance (IR) was calculated using the following formula:
HOMA-IR (Homeostasis model assessment of insulin
resistance) = [Fasting plasma insulin (μU/mL) × FPG (mg/
dL)] / 405 with a cut-off value of 2.6 [11].
Blood samples were drawn after an 8 h fast. Plasma
glucose concentration was assessed using the hexokinase
method with Abbott Architect ci16200 automatic analyzer
(Diamond Diagnostics, Holliston, MA, USA). HbA1c was
measured by a turbidimetric inhibition immunoassay
(TINIA) (Roche Diagnostics, Mannheim,Germany).
OGTT was performed in all patients who were not already
diagnosed with diabetes. Patients were told to ingest at
least 150 g/day of carbohydrates for 3 days prior to the test.
OGTT was performed in the morning between 7 and 9
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AM after 8 h overnight fasting. Blood samples were drawn
before and 60, 120, and 180 min after the ingestion of 75
g glucose.
2.2. Statistical analysis
After data distributions were tested, parametric
distributions were expressed as mean ± standard deviation,
nonparametric distributions were expressed as median
(interquartile range), and categorical parameters were
expressed as percentage. Chi-square tests were performed to
compare categorical parameters. The independent samples
t-test and Mann–Whitney U Test were used to compare
noncategorical parameters between diabetic and normal
glucose tolerance patients, and between MetS positive and
negative patients. Pearson and Spearman correlations were
used to determine the relationships between variables.
Binary regression analysis was performed to determine the
risk factors for MetS development. Statistical significance
was set at P < 0.05. All statistical analyses were performed
using the SPSS 21.0 version (Statistical Package for Social
Sciences, IBM Corp., Armonk, NY, USA).
3. Results
Demographic characteristics and laboratory values of
study participants are presented in Table 1. A total of 67
patients with previous GDM were analyzed 10 ± 2 years
postpartum. A total of 27 patients developed diabetes
(40.3%), 13 developed prediabetes (IFG and/or IGT)
(19.4%), and 27 had normal glucose tolerance. T2DM
developed, on average, 4.8 years after delivery. MetS
developed in 52.2% (n = 35) of the patients.
Eleven women (16.4%) gave birth to a macrosomic
baby, 44 (65.7%) underwent caesarean section, 13 (19.4%)
had obstetric problems during pregnancy or labor, 27
(40.3%) had preterm labor, and 11 (16.4%) had babies with
health issues (prolonged jaundice, hypoglycemia, asphyxia,
and/or growth retardation). Fifty-four patients (80.6%)
had a family history of DM. Thirty patients (44.8%) were
treated with insulin during pregnancy. As for the patients’
current medication: 14 patients (20.9%) were on insulin
treatment, 35 patients (52.2%) used an oral antidiabetic,
11 (16.4%) used an antihypertensive, and 5 (7.5%) used a
lipid lowering drug.
There was no significant difference in the mean levels of
BMI and HOMA-IR between diabetes-developing patients
and nondiabetic patients. The rate of antihypertensive
drug use was 29.6% in patients with diabetes and 7.5%
in patients without diabetes (P = 0.022). As for obstetric
histories, there was no significant difference between
diabetic and nondiabetic patients in terms of weight gain
during pregnancy, history of diabetes in a first degree
relative, or fetal macrosomia (P > 0.05). However, there was
a significant difference between diabetic and nondiabetic
patients in terms of insulin use during pregnancy (P <

0.001) (Table 2). Of those patients with current DM, 77.8%
used insulin during their pregnancy (n = 21/27). Excluding
the 13 patients who had IFG and/or IGT, only 7 (25.9%)
women with normal glucose tolerance used insulin while
pregnant. Women who developed diabetes within 10 years
after delivery were observed to have significantly higher
FPG levels on OGTT during their pregnancy (Table 2).
Subgroup analysis regarding the development of MetS
revealed that weight gain during pregnancy and maternal
age showed no significant difference (P = 0.051). On
the other hand, current and pregestational BMI values
showed a significant difference between MetS positive
and MetS negative patients (Table 3). Binary regression
analysis regarding obstetric risk factors revealed that fetal
macrosomia, type of birth, time of birth, history of diabetes
in a first degree relative, and insulin use in pregnancy had
no significant effect on the development of MetS 10 years
after delivery (Odds ratio; 95% CI and P values are: 0.483;
0.123–1.895, P = 0.297, 1.193; 0.450–3.162, P = 0.723,
1.202; 0.423–3.416, P = 0.730, 1.786; 0.504–6.335, P =
0.369, and 1.723; 0.592–5.018, P = 0.318, respectively).
Obstetric history and BMI of patients with and without
insulin resistance are shown in Table 4.
4. Discussion
In this study, we found that approximately 60% of prior
GDM patients developed diabetes or prediabetes while
50% developed MetS over a period of 10 years. Our
finding is in line with literature where the cumulative
incidence of T2DM development over 5 years is reported
to be approximately 50% [12,13]. Our rate of progression
to MetS is also consistent with previous reports [14,15].
Current guidelines recommend screening GDM patients
with OGTT 4–12 weeks after delivery and then every
1–3 years [16]. However, there is no consensus as to how
long GDM patients should be monitored. In our study,
diabetes developed, on average, 4.8 years after delivery. In
agreement with this result, the rate of GDM progression
to T2DM is reported to be highest during the first 5 years
after delivery, with a slower increase after 10 years [12].
We therefore recommend annual screening for the first 5
years after GDM for high-risk patients.
Fasting plasma glucose on OGTT is the factor most
commonly linked with progression to T2DM [12].
Furthermore, BMI, waist circumference, gestational
insulin use, and early gestational age at the time of GDM
diagnosis have all been associated with the development
of T2DM in patients with GDM [17,18]. A retrospective
cohort study reported that maternal age at delivery and
birth weight of the baby were also associated with diabetes
development [19], but contradictory findings exist [20]. In
line with the literature, our data suggest that progression
to T2DM is mainly determined by higher FPG levels and
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Table 1. Demographic characteristics and laboratory measurements of the
participants.
Mean ± SD
or median (IQR)

Min-max

Age (years)
· Current
· At pregnancy

42.1 ± 5.3
31.8 ± 5.3

32.0–54.0
20.0–42.5

BMI (kg/m2)
· Current
· Before pregnancy

30.4 ± 5.3
26.7 ± 5.0

20.5–46.1
18.3–40.1

Weight gain during pregnancy (kg)

12.0 (70–15.0)

(–10.0)–27.0

Birth weight (kg)

3.45 (2.85–3.75)

1.50–5.50

Waist circumference (cm)

96.9 ± 11.5

70.0–125

Waist/hip ratio

0.88 ± 0.06

0.76–1.05

Smoking intensity (pack-years)

5.5 (4.25–20)

1–30

Blood pressure (mmHg)
· Systolic
· Diastolic

122 ± 18
78 ± 10

90–200
60–100

Total cholesterol (mg/dL)

198 ± 37

115–301

Triglyceride (mg/dL)

120 (79–148)

40–402

LDL-cholesterol (mg/dL)

121 ± 32

69–221

HDL-cholesterol (mg/dL)

49 (43–64)

30–88

HbA1c (%)

6.5 ± 1.5

5.3–13.8

C-peptide (ng/mL)

2.06 (1.1–3.1)

0.03–9.1

FPG during pregnancy (mg/dL)

95 (84–125)

53–243

HOMA-IR

1.69 (1.14–3.45)

0.40– 9.84

TSH (mIU/L)

1.95 (1.41–2.82)

0.42–7.6

fT4 (pmol/L)

14.7 ± 2.1

8.6–20.1

The results were calculated using logarithmic transformations. Mean ± SD; mean
± standard deviation.
Unless otherwise specified in the table, the variables show measurements at the
time of the study.
BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density
lipoprotein; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin A1c;
HOMA-IR: homeostasis model assessment of insulin resistance; TSH: thyroidstimulating hormone; fT4: free thyroxine.

insulin use during pregnancy. Of the patients with current
T2DM, 77.8% were prescribed insulin during pregnancy.
This ratio was 25.9% for those with normal glucose
tolerance. Women with GDM have been shown to have
chronic insulin resistance and β-cell dysfunction [21].
Elevated FPG during pregnancy suggests insulin resistance,
while insulin requirement indicates an impaired β-cell
function. As a result, FPG and insulin use may be related
to the severity of GDM and hence predict the likelihood of
progression to T2DM. There is evidence that T2DM and
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the resulting cardiovascular disease can be prevented with
lifestyle changes or medical therapy [13,22]. Also of note
is that awareness improves adherence to lifestyle changes
[23]. We therefore recommend that high-risk patients (i.e.
patients with higher FPG and those who require insulin
treatment during pregnancy) be informed about their
individual risk of developing diabetes.
In our study, BMI, HOMA-IR scores, weight gain
during pregnancy, history of diabetes in a first degree
relative, and fetal macrosomia were not related to the
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Table 2. Demographic characteristics, laboratory measurements, and obstetric history of patients with and without
T2DM.
Diabetic (n = 27)
Mean ± SD
or median (IQR)

Normal glucose tolerance
(n = 27) Mean ± SD
or median (IQR)

P value

Age (years)
· Current
· At pregnancy

43 ± 5.7
32 ± 5.7

41 ± 4.8
32 ± 5.0

ns†
ns†

BMI (kg/m2)
· Current
· Before pregnancy

30.7 ± 5.6
26.5 ± 5.6

30.0 ± 5.7
26.4 ± 5.2

ns†
ns†

Waist circumference (cm)

97.7 ± 11.1

95.1 ± 11.3

ns†

Blood pressure (mmHg)
· Systolic
· Diastolic

126 ± 21
78 ± 11

118 ± 16
76 ± 9

ns†
ns†

Triglyceride (mg/dL)

125 (98–170)

105 (69–144)

ns††

HDL cholesterol (mg/dL)

49 (37–65)

54 (46–64)

ns††

HOMA-IR

1.9 (0.9–4.7)

1.5 (1.3–2.2)

ns††

C-peptide (ng/mL)

2.0 (0.7–3.2)

2.2 (1.5–3.3)

ns††

Birth weight of the infant (g)

3500 (2750–3750)

3450 (3150–3800)

ns††

FPG during pregnancy (mg/dL)

125 (96–152)

88 (81–100)

P = 0.007††

Weight gain during pregnancy

10 (7–15)

13 (9–17)

ns††

Smoking intensity (pack-years)

15 (5–21)

4.5 (1.75–10.25)

ns††

Family history of T2DM (%)

85.2

81.5

ns**

Insulin requirement during pregnancy (%)

77.8

25.9

P < 0.001**

The results were calculated using logarithmic transformations. Mean ± SD; mean ± standard deviation.
Unless otherwise specified in the table, the variables show measurements at the time of the study.
IQR: interquartile range; T2DM: type 2 diabetes mellitus.
ns: nonsignificant.
†
The independent samples t-test was used, ††Mann–Whitney U Test was used, **chi-square test was used.

development of T2DM. Similarly, Rayanagoudar et al.
report in their systematic review that gestational glycemic
status is the main determinant of T2DM risk in the future,
and that gestational weight gain or macrosomic infant do
not increase the risk [24]. Also in line with our findings,
most studies have failed to establish a relation between
family history of T2DM and progression to diabetes
[12]. However, several studies have linked obesity to the
future risk of T2DM [25]. GDM patients who come to
our hospital are monitored closely and are asked to adhere
to a strict diet, which may have limited their weight gain
during, and after pregnancy. Ethnicity, dietary habits, and
the prevalence of obesity in our country may also have
affected our results.
We found that patients with higher HOMA-IR scores
had significantly higher BMI, pregestational BMI, and
maternal age compared to patients without IR. IR is a well-

known precursor of T2DM. However, our results suggest
that IR alone has limited power to predict transition from
GDM to T2DM. This is probably due to other factors
involved in the transition, such as pancreatic β-cell reserve
and the polygenic inheritance of T2DM [9].
As for the relation between IR and dyslipidemia, we
found that patients with HDL <50 mg/dL and triglyceride
≥150 mg/dL had significantly higher HOMA-IR scores
than patients with HDL ≥50 mg/dL and triglyceride
<150 mg/dL. Presence of dyslipidemia, antihypertensive
drug use, or smoking status did not differ among these
two groups. Our results were as expected, since the
typical dyslipidemia of insulin resistant state involves
hypertriglyceridemia and low HDL.
We found that diabetic patients had a higher rate of
antihypertensive drug use. Diabetes and hypertension were
possibly found together in the same individual due to shared
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Table 3. Demographic characteristics, laboratory measurements, and obstetric history of patients with and without MetS.
MetS (+) (n = 35)
Mean ± SD or
median (IQR)

MetS (-) (n = 32)
Mean ± SD or
median (IQR)

Age (year)
· Current
· At pregnancy

43 ± 4.7
33 ± 4.7

41 ± 5.6
31 ± 5.7

0.054†
0.051†

BMI (kg/m2)
· Current
· Before pregnancy

32.8 ± 5.0
28.2 ± 5.1

27.8 ± 4.4
24.7 ± 4.2

0.003†
0.027†

Weight gain during pregnancy (kg)

10.0 (6.0–14.0)

14.0 (9.2–15.7)

0.051††

Waist/hip ratio

0.91 ± 0.05

0.85 ± 0.05

0.006†

Smoking intensity (pack-years)

5.0 (2.0–20.0)

6.0 (4.5–20.0)

0.749††

HbA1c (%)

7.1 ± 1.9

5.9 ± 0.7

<0.001†

HOMA-IR

2.75 (1.94–4.75)

1.24 (0.73–1.64)

<0.001††

C-peptide (ng/mL)

2.77 (2.06–3.60)

0.70 (0.34–1.31)

<0.001††

Birth weight of the infant (g)

3350 (2850–3650)

3450 (3040–3937)

0.580††

Family history of DM (%)

86

75

0.268**

Insulin requirement during pregnancy (%)

51

37

0.252**

P value

The results were calculated using logarithmic transformations. Mean ± SD; mean ± standard deviation. P < 0.05 statistically
significant.
Significant P values are shown in bold. Unless otherwise specified in the table, the variables on the table show measurements
at the time of the study. MetS: metabolic syndrome
†
The independent samples t-test was used, ††Mann–Whitney U test was used, **chi-square test was used.
Table 4. Comparison of BMI and obstetric history of patients with and without insulin
resistance.
HOMA-IR
≥2.6 Mean ± SD
(n = 24)

<2.6 Mean ± SD
(n = 42)

P value

BMI (kg/m2)

32.8 ± 4.9

28.9 ± 5.1

0.003*

Pregestational BMI

28.7 ± 4.9

25.2 ± 4.6

0.002*

Age at pregnancy

33.5 ± 4.1

30.8 ± 5.7

0.003*

Mean ± SD; mean ± standard deviation. P < 0.05 statistically significant. Significant P
values are shown in bold.
*The independent samples t-test was used.

etiological factors including obesity, inflammation, and
oxidative stress. Moreover, insulin resistance is known to be
effective in the development of both T2DM and hypertension.
Coexistence of T2DM and hypertension can also be
explained genetically, since there is evidence indicating that
variants of angiotensinogen and adrenomedullin gene are
associated with both conditions [26].
Metabolic syndrome is a cluster of abdominal obesity,
insulin resistance, dyslipidemia, and hypertension.
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Previous studies have shown that the development of
MetS in GDM patients is associated with current and
pregestational BMI [27,28]. In agreement with literature,
current and pregestational BMI had a significant effect
on the development of MetS in our study. Adipose
tissue is known to secrete adipokines, which are
involved in inflammatory processes. It is probably due
to these adipokines that subclinical inflammation, IR,
and endothelial dysfunction, all of which lead to the
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development of MetS, are greater in previously obese
GDM patients. There is also evidence suggesting that
GDM and MetS may have a common genetic background.
A relationship between GDM and the risk gene variants
is similarly present in MetS [29]. Our results suggest that
this genetic predisposition may be more evident in obese
individuals. Since obesity is a modifiable risk factor,
high-risk patients may benefit from lifestyle changes and
medical intervention to prevent MetS.
A byproduct of insulin synthesis, C-peptide has
previously been studied as a sensitive indicator of MetS
[30]. Similarly, we found that C-peptide levels of MetS
patients were significantly different compared to the group
of patients without MetS. This difference may be explained
by the fact that plasma C-peptide concentrations correlate
better with β-cell function during insulin resistance. In
addition, C-peptide is known to regulate inflammatory
cytokines and may thus have a correlation with MetS,
which, as previously mentioned, is a chronic low-grade
inflammatory state [31]. The clinical implication of this
easy laboratory tool is that it may be used to identify
patients at risk of developing MetS. As we only had
information on patients’ current C-peptide levels, further
studies comparing C-peptide concentrations before and
after pregnancy are needed to be able to draw conclusions.
In our study, obstetric risk factors such as fetal
macrosomia, type of birth, time of birth, history of diabetes
in a first degree relative, insulin use during pregnancy,
weight gain during pregnancy, and maternal age had no
significant effect on the development of MetS, which is
in agreement with the literature [32]. The relationship
between insulin use and T2DM development was probably
not strong enough to be effective in the development of
MetS, which is a cluster of several risk factors.
Finally, our study has several limitations worth
mentioning. First of all, the relatively small sample size
was a limitation of this study. A larger study population
could reveal novel associations that our study failed to
demonstrate. Presence of cardiovascular risk factors
following pregnancy was not evaluated due to the
retrospective design of the study. Another limitation was
lack of information about the glycemic control of GDM

patients during pregnancy. However, our medical center
is a university hospital with a highly experienced team of
endocrinologists who check GDM patients on a weekly
basis to ensure best possible glycemic control. It is also
worth mentioning that the exclusion of pregestational
diabetes was based on HbA1c values for only 18 GDM
patients. For the rest of the patients, the exclusion was based
on patient history. However, when we reevaluated GDM
patients with high FPG, we found that only one of them
developed post gestational T2DM, making pregestational
diabetes an unlikely diagnosis. The only patient with
high FPG who developed T2DM after pregnancy had a
pregestational HbA1c of 5%; hence none of the patients
were suspected to have pregestational diabetes.
Lack of objective data regarding the prevalence of MetS
before pregnancy presents a major limitation to the study.
Other than pregestational BMI and FPG values, MetS
diagnosis was excluded based on patient history. Patients
with established dyslipidemia, hypertension, diabetes, or
with related drug use did not fulfill the eligibility criteria.
Therefore, although not definite, patients included in
the study were assumed to not have had MetS before
pregnancy.
To the best of our knowledge, this is the first long-term
study to associate GDM with both T2DM and MetS in our
country. Previous GDM studies in literature mostly focus
on the metabolic state at the early postpartum period or
just a few years after delivery [33,34] while few studies
present a long-term evaluation [19,20]. Our 10 year
follow-up time was a strength of the study.
In conclusion, effective postpartum follow-up of
patients diagnosed with GDM is essential since GDM may
progress to T2DM and MetS, both of which are major
public health problems. We found in this long-term study
that patients with high FPG and insulin requirement
during pregnancy are at an increased risk of developing
T2DM, while pregestational obesity is predictive of
progression to MetS. Identifying and targeting highrisk individuals may delay and possibly prevent T2DM
and MetS. Future prospective studies with larger study
populations are warranted to clarify the contradictory
findings in literature.
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